TRPV1 and glioblastoma: Since different mechanisms mediate the resistance of GSCs to cytotoxic therapies and to pro-apoptotic signals [40-42], including down-regulation of TRPV1 [23], this data suggest that reduced TRPV1 expression in GSCs could be associated to their acquired resistance, as in GBM.